无托槽隐形矫治微型测力系统的建立

目的 建立无托槽隐形矫治微型测力实验平台,以测量矫治过程中牙齿的应力.方法 开发基于硅衬底的应力传感器芯片,随后进行芯片减薄,并采用四点弯曲结构进行压阻系数标定,使用超薄的柔性电路板封装传感器芯片,引出信号,搭建完整的隐形矫治应力测量实验平台.结果 制造完成的应力传感器芯片长7.0 mm、宽6.0 mm、厚0.1mm,其上包括13个注入制造的单晶硅压阻应力敏感单元和4个标定单元;设计制造了基于多路选择电路的主测试电路板,搭建了完整的隐形矫治应力测量实验平台,通过压阻阻值的测量计算出13个测量单元位置所在的应力.结论 建立了无托槽隐形矫治微型测力系统的实验平台,为精确测量矫治过程中牙齿的局部应力提供了方法.     

Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer

Background

Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, and sorafenib, a RAF kinase inhibitor, has shown efficacy in renal cell cancer (RCC) as single agents. We conducted a phase I study to evaluate the maximum tolerated dose (MTD) of combining these agents for potential additive or synergistic effects when treating progressive metastatic RCC (mRCC).

Patients and Methods

The 15 patients enrolled in the study had predominantly clear cell RCC (cRCC) and progressive measurable disease with previous treatment that included immunotherapy, tyrosine kinase inhibitors, and/or everolimus. Patients received daily everolimus and twice-daily sorafenib at escalating dose levels of 2.5 mg/400 mg (cohort 1), 5 mg/400 mg (cohort 2), and 10 mg/400 mg (cohort 3), and they were evaluated weekly for toxicity and every 8 weeks for response, using computed tomography/positron emission tomography (CT/PET) and CT at baseline and at first staging.

Results

In cohort 1, 2 of 6 patients experienced dose-limited toxicity (DLT) of thrombocytopenia/leukopenia and pneumonitis. In cohort 2, 1 of 6 patients experienced a DLT of pulmonary embolism, and the 3 patients in cohort 3 experienced no DLTs. The MTD was 10 mg/400 mg. Common adverse events included grade 1/2 hand-foot syndrome. Using Response Evaluation Criteria in Solid Tumors (RECIST), 1 patient achieved a pathologic complete response (CR), 1 patient achieved a radiographic CR, and 1 patient achieved a surgical CR. Seven patients achieved stable disease; 10 patients had decreased fluorine-18 fluorodeoxyglucose uptake. Median progressive-free survival was 5.6 months; overall survival was 7.9 months.

Conclusion

The MTD of daily everolimus 10 mg and twice-daily sorafenib 400 mg is safe and effective for progressive mRCC.     

脊柱结核外科治疗骨缺损的修复

背景：脊柱结核外科干预治疗中如何有效修复破坏之椎体,是脊柱结核治疗中的重点和难点。 目的：探讨国内目前脊柱结核病灶清除后骨缺损修复方法、骨缺损修复的有效方法及新进展。 方法：CNKI数据库检索2006/2010-01-01五年间相关脊柱结核外科治疗文献,先检索关键词“脊柱结核”,再分别以：“内固定”,“植骨”,“人工骨(材料)”,“钛网”, “骨水泥”,“人工椎体”,为关键词在以上数据中检索,根据入选条件,选择相关文献,对其文献报道病例、手术方法(包括骨修复方法)、疗效(包括治愈率、复发率、Cobb角纠正)进行统计分析。 结果与结论：自体骨(髂骨、肋骨)是脊柱结核目前骨缺损的主要修复来源,其次是钛网植骨,人工骨及人工椎体少量用于临床治疗。提示,自体骨仍是脊柱结核骨缺损修复的主要来源,是钛网植骨次之,人工骨及人工椎体有广阔的发展空间,成为将来植骨理想替代品。     

红蓝光联合陈氏粉刺清治疗痤疮的疗效观察

目的：探讨联合应用红蓝光及陈氏粉刺清治疗炎症性痤疮的临床效果。方法：选择中重度（Pillsbury分级为II或III度）寻常性痤疮92例,随机分为试验组（46例）和对照组（46例）。试验组采用红蓝光与陈氏粉刺清联合治疗,对照组单用陈氏粉刺清治疗,研究分析其治疗效果。结果：总体效果评价中,试验组痊愈率为21．7％,有效率为82．6％;对照组痊愈率为1o．8％,有效率为54．3％,比较两组之间痊愈率及有效率均有显著性差异（P〈0．05）。结论：红蓝光与粉刺清联合治疗炎症性痤疮疗效好,其疗效明显优于单用粉刺清治疗,不良反应亦轻微。     

耳穴贴压治疗失眠症的研究进展

目的：探讨近年耳穴贴压治疗失眠症的机理研究及临床治疗情况。方法：通过对近年来有关耳穴贴压治疗失眠症的机理研究及治疗情况的文献进行分析总结。结果：耳穴贴压具有调节脏腑经络功能、神经功能、血管功能等多方面作用,临床应用较为广泛。结论：耳穴贴压治疗失眠症,疗效显著,操作方便,无不良反应,患者易于接受。     

Primary mediastinal clear cell lymphoma

Summary This is a report on 8 mediastinal tumours that occurred in young adults (19–43 years, mean: 29.4); predominantly in females (6/8). Initial symptoms consisted of thoracic pain and venectasia and in only one case in B symptoms. After surgical tumour reduction, radiation and/or chemotherapy, local recurrence was observed in each case under clinical care; abdominal spread is presently suspected in 3 patients; 3 died 11, 13 and 22 months after diagnosis. None developed leukaemia. The tumours are B-cell neoplasms with a characteristic immunophenotype: leucocyte common antigen⁺, common acute lymphoblastic leukaemia antigen^–, B 1-antigen⁺, surface and cytoplasmic immunoglobulin^–. Flow cytometry revealed DNA-diploidy in 7 cases and a moderately (3.2–3.8%) to extremely high (8.0–20.6%) S-phase component. The proliferation associated antigen Ki67 was detectable in 10–60% of the tumour cell nuclei, thus stressing the considerable or rapid growth. Histopathology is characterized by a diffuse growth pattern and a clearness and abundance of cytoplasm of the pleomorphic tumour cells, which vary in size and nuclear morphology from patient to patient. Apoptoses are more numerous than mitoses. Fibrosis and focal necrosis are common, sclerosis is present in 3 cases. We suggest that primary mediastinal lymphoma of B cell type is a novel B-lymphoma variant.This work was supported by the Tumorzentrum Heidelberg/Mannheim and the Land ofThis work was supported by the Tumorzentrum Heidelberg/Mannheim and the Land of     

Clear cell chondrosarcoma of bone

We report 8 cases of clear cell chondrosarcoma from 350 cases of chondrosarcoma (2.2%) seen at Istituto Rizzoli. The lesion is always low grade in nature and occurs in an epiphyseal location, usually in the proximal femur or humerus. This relatively inaccessible location may hinder the exact diagnosis. Wide resection is the treatment of choice, although 3 of our patients underwent intralesional or marginal procedures. At present all patients are free of disease. However, a longer follow-up is essential because of the slow-growing nature of this sarcoma.     

小儿肾脏透明细胞肉瘤的超微结构观察

自１９９０年６月￣１９９３年７月，对５例小儿肾脏透明细胞肉瘤进行了光镜及电镜观察。结果表明，发生于婴儿及儿童的ＣＣＳＫ是一种在光镜，电镜下形态不同于Ｗｉｌｍｓ‘瘤的恶性肿瘤，对其形态结构特点进行了讨论，并强调其鉴别诊断作用。     

Clear cell meningioma of the lumbo-sacral spine with chordoid features

Clear cell meningioma (CCM) is a peculiar variant that differs from conventional meningioma in affecting younger patients, arising more often in spinal or cerebellopontine locations, and showing a higher recurrence rate. Classical meningothelial areas are scarce in these tumors and the differential diagnosis with other neoplasms, particularly metastatic carcinoma, is often difficult. We report a case of clear cell meningioma from the lumbosacral spine in which location, radiologic presentation, light microscopic appearance in initial sampling, and some of the ultrastructural findings were reminiscent of chordoma. The tumor cells were diffusely positive for vimentin and very focally positive for epithelial membrane antigen. Ultrastructural demonstration of interdigitating cell processes joined by numerous desmosomes confirmed the diagnosis of CCM.